Xeris Pharmaceuticals Inc represents a commitment to innovation, patient care, and delivering life-changing solutions in the pharmaceutical industry. With a focus on developing therapies for patients with complex and chronic conditions, Xeris Pharmaceuticals prioritizes patient safety and therapeutic effectiveness. The company embraces a patient-centered approach by developing products that address unmet medical needs and improve patients' quality of life. Xeris Pharmaceuticals also values collaboration with healthcare professionals, fostering partnerships to advance research and development. By staying at the forefront of pharmaceutical innovation, Xeris Pharmaceuticals aims to provide accessible and effective treatments for patients worldwide.

Xeris Pharmaceuticals Inc is primarily present in the United States.

Xeris Pharmaceuticals Inc has achieved several significant milestones since its establishment. The company successfully launched its first commercial product, Gvoke® as a treatment for severe hypoglycemia in 2019. Xeris Pharmaceuticals also received FDA approval for Ogluo™, a ready-to-use liquid glucagon product, in 2020. Furthermore, the company has made progress in developing its proprietary XeriSol™ and XeriJect™ formulations, which aim to improve the delivery of known pharmaceutical compounds. Xeris Pharmaceuticals continues to advance its pipeline, focusing on developing innovative solutions for various acute and chronic diseases.

Xeris Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing innovative therapies for various medical conditions. Established in 2005, Xeris has emerged as a leader in the biopharmaceutical industry, dedicated to providing novel treatment options. The company's mission revolves around addressing unmet medical needs by developing solutions that enhance patient outcomes and improve quality of life. Xeris Pharmaceuticals Inc has built a strong reputation for its groundbreaking research and development initiatives, collaborating with experts and organizations worldwide. With a focus on cutting-edge technologies and a commitment to advancing healthcare, Xeris Pharmaceuticals Inc continues to make significant strides in the pharmaceutical landscape.

The main competitors of Xeris Pharmaceuticals Inc in the market are other pharmaceutical companies that operate in the same therapeutic areas. Some notable competitors include AstraZeneca, Eli Lilly and Company, Novo Nordisk, and Sanofi. Xeris Pharmaceuticals Inc competes with these companies in developing innovative solutions for diabetes and other endocrine disorders. With its focus on novel delivery technologies, Xeris Pharmaceuticals Inc aims to differentiate itself from its competitors and provide value to patients and healthcare providers.

Xeris Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Xeris Pharmaceuticals Inc. is a pharmaceutical company specializing in developing and commercializing ready-to-use injectable and infusible drug formulations. Their innovative technology allows the development of products that can be administered without reconstitution or dilution. Xeris Pharmaceuticals Inc. aims to improve patient care by providing convenient, safe, and effective treatments for various medical conditions. With their focus on developing stable and room-temperature stable formulations, the company aims to simplify drug administration and enhance patient compliance. Xeris Pharmaceuticals Inc. is committed to advancing its pipeline and collaborating with partners to bring cutting-edge therapies to market.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Xeris Pharmaceuticals.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Xeris Pharmaceuticals.

Το AlleAktien Qualitätsscore για το Xeris Pharmaceuticals είναι 4/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Xeris Pharmaceuticals.

Τα κέρδη για τον Xeris Pharmaceuticals δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Xeris Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapies for patients with diabetes and endocrine disorders. Founded in 2005 in Austin, Texas, the company actively works on developing drugs that aim to make insulin therapy more effective and safer. Xeris Pharmaceuticals Inc's business model is based on the development and distribution of novel medications. The company is divided into several divisions, including diabetology, endocrinology, and pediatrics. Xeris' products are primarily targeted towards the US market, where there is a growing demand for innovative diabetes therapies. The company's flagship product is the glucagon rescue pen, a medication used for hypoglycemia. Hypoglycemia occurs when a diabetic patient's blood sugar level is too low. The glucagon rescue pen is used in emergencies to quickly and effectively help the individual. The medication is easy to use and does not require specialized knowledge for application. Another important product from Xeris Pharmaceuticals Inc is the G-Pen Mini, specifically designed for children with diabetes. The G-Pen Mini is the first glucagon rescue pen specifically designed for children, simplifying the application and dosage of glucagon in emergencies. In addition to these products, Xeris Pharmaceuticals Inc is also working on the development of novel insulin products. Insulin is a hormone needed by diabetics to control their blood sugar levels. Xeris has developed a new formulation of insulin that will be launched in the form of a self-injectable pen, making it easier for diabetics to dose their insulin. Another area of focus for Xeris Pharmaceuticals Inc is researching medications for excessive adrenaline production in children. Adrenaline is a hormone released by the body to cope with stressful situations. However, some children with endocrine disorders produce too much adrenaline, which can lead to serious health problems. Xeris is actively working on developing a new medication to treat this condition. Xeris Pharmaceuticals Inc is an innovative company that constantly focuses on the development of new therapies. With a dedicated research department and a strong team of leaders, Xeris positions itself as a leader in diabetes therapy. Through consistent product development and marketing, Xeris Pharmaceuticals Inc will continue to be successful with its proven business model.

Η Xeris Pharmaceuticals καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Xeris Pharmaceuticals αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Xeris Pharmaceuticals είναι US98422L1070.

Το WKN της Xeris Pharmaceuticals είναι A2JPE9.

Ο τίκερ της Xeris Pharmaceuticals είναι XERS.

Κατά τους τελευταίους 12 μήνες η Xeris Pharmaceuticals κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Xeris Pharmaceuticals προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Xeris Pharmaceuticals ανέρχεται σήμερα στο .

Xeris Pharmaceuticals πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Xeris Pharmaceuticals πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Xeris Pharmaceuticals ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Xeris Pharmaceuticals από την 8/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 8/9/2024.

Η τελευταία μερίσματος έγινε στις 8/9/2024.

Το έτος 2023, η Xeris Pharmaceuticals διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Xeris Pharmaceuticals καταβάλλονται σε USD.